Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Biopharmaceutical company initiates clinical trial of TRX4 for psoriasis
September 5th, 2004
TolerRx, Inc., a biopharmaceutical company, announced the initiation of a phase 1 trial of its TRX4 monoclonal antibody in subjects with psoriasis. This phase 1 trial will be a single-dose, dose-escalation study to establish the safety, pharmacokinetic, and pharmacodynamic profile of TRX4. Approximately thirty moderate to severe psoriasis subjects will be enrolled. The clinical trial is being conducted pursuant to an investigational new drug (IND) application filed with the U.S. Food and Drug Administration. TRX4 is a humanized monoclonal antibody that binds to a receptor found on all mature T cells called CD3, which is involved in normal T cell...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
